Our study, together with further exploration on the membrane-bound c-Abl environment, may offer a potential application to discover new targets for cancer therapy because the Bcr-Abl distribution in Bcr-Abl+ chronic myelogenous leukemia cells is cytosolic, and these cells are resistant to apoptotic events. This evidence concerns the gene ABL1 and cancer.